SCHEMBL651407

SCHEMBL651407

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(OC(F)F)cc1)Cc1cccc(OC(F)(F)C(F)F)c1

nearest known ligand 0.42

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.42
CETP P11597 18/20 0.40
CRHR1 P34998 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL650074 0.95 C5AR1 (0.43) C5AR1CETPCRHR1
SCHEMBL652216 0.94 C5AR1 (0.42) C5AR1CETPCRHR1
SCHEMBL648790 0.94 C5AR1 (0.43) C5AR1
SCHEMBL650193 0.93 CRHR1 (0.40) C5AR1CETPCRHR1
SCHEMBL648222 0.91 C5AR1 (0.43) C5AR1CRHR1
SCHEMBL648926 0.91 C5AR1 (0.41) C5AR1CETP
SCHEMBL650072 0.91 C5AR1 (0.41) C5AR1CETP
SCHEMBL650285 0.91 C5AR1 (0.41) C5AR1CRHR1
SCHEMBL648123 0.90 C5AR1 (0.42) C5AR1CETPCRHR1
SCHEMBL651956 0.90 C5AR1 (0.43) C5AR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed